3 US Biotech Stocks Investors Are Screening As China Capital Rules Tighten

Washington just threw a new spotlight on biotech and pharma by tightening proposed rules on US money flowing into sensitive Chinese technologies, which puts fresh attention on where capital is allowed to grow and where it might hit a wall. That shift creates an opening for investors who focus on US-listed stocks tied more closely to domestic science and funding. This article walks through three companies exposed to this policy story and explains how the news could matter for your portfolio decisions.

The stocks covered below are just a small sample, and the full screen surfaced 46 more US-listed biotech and pharma companies with equally compelling stories tied to this policy shift. To identify and analyze the highest conviction ideas that fit your own risk and return preferences, head straight into the US-Listed Biotech and Pharma with Primarily Domestic or Non-China Focus screener.

Krystal Biotech (KRYS)

Krystal Biotech fits this screener neatly because it is a US-listed genetic medicines player built around complex cell and gene therapies. That gives you a pure domestic biotech story right as policy steers more capital away from China-exposed research platforms.

Krystal Biotech generates all of its roughly US$440 million in revenue from discovering, developing, manufacturing and commercializing genetic medicines, and the business currently earns that revenue entirely in the United States. The company’s market cap sits around US$9.5b.

"Further international rollout of Vyjuvek, including ongoing work to enter additional European markets such as Italy and Spain and to finalize pricing in countries like Germany, could add new rare disease revenue streams and support earnings from outside the United States. Planned expansion of the HSV 1 platform into oncology and additional rare disease indications, including a registrational study for KB707 in second line non small cell lung cancer and multiple late stage programs, will require higher development and commercial spending. This could compress earnings if revenue from new products does not arrive at the pace implied by current margin and cash balance figures."

What happens when that extra spending hits at the same time as one subtle pressure on future profitability starts to bite will be crucial.

That profit squeeze risk is only half the picture, and the full narrative for Krystal Biotech explains how Krystal Biotech could still accelerate if its pipeline and spending decouple cleanly.

Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics aligns directly with this screener’s focus on advanced oncology and cell therapies. The company offers a US-led tumor infiltrating lymphocyte platform that is already commercial and expanding, which is why it draws extra interest as policy steers capital toward domestically oriented biotech stories.

Iovance Biotherapeutics generates about US$325 million from developing and commercializing autologous tumor infiltrating lymphocyte therapies for solid tumors, anchored by Amtagvi and Proleukin, and the stock carries a roughly US$6.6b market cap.

"Amtagvi is already approved in the United States and is the first TIL (tumor-infiltrating lymphocyte) therapy available for patients with advanced melanoma, so the company has moved beyond the biggest hurdle that many biotech companies never overcome."

What happens next for Iovance Biotherapeutics rests heavily on how one less visible constraint shapes the real pace of that commercial rollout.

That hidden constraint is exactly what the full narrative for Iovance Biotherapeutics unpacks, showing where Iovance Biotherapeutics could accelerate or stall as the rollout and capital needs collide.

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics gives this screener a pure-play gene editing force that is US-listed, focused on advanced biotech fields like hemoglobinopathies, CAR T therapies and in vivo programs, and currently earns about US$13 million from discovering, developing and commercializing therapies, with a roughly US$4.8b market cap.

CRISPR Therapeutics matters for this policy-driven screen because it offers US investors a focused gene editing story tied to sensitive biotech fields at a time when capital is being nudged toward domestically oriented platforms.

"Expansion of CASGEVY to pediatric patients as young as 2 years old and a growing base of more than 75 authorized treatment centers worldwide increase the pool of eligible sickle cell and beta thalassemia patients, which can support higher future revenue and improve earnings leverage as fixed infrastructure is used more fully."

What happens if one still unresolved pressure around future financing choices collides with that growing treatment footprint will matter for long term returns.

That financing question is exactly where the full narrative for CRISPR Therapeutics picks up, laying out how CRISPR Therapeutics could balance funding needs with an accelerating gene editing opportunity set.

Seeking Alternatives Before Others Catch On

Fresh ideas move fast. Breakout momentum often flies under the radar for now and information advantage drops once the crowd catches up, so scan new angles and act now.

• Spot under-the-radar compounding potential by running through the 30 high quality undervalued stocks while the gap between quality and price still matters for long term returns.
• Ride the real earnings momentum behind next-wave automation by filtering opportunities with the 93 robotics and automation stocks before capital chases the same stories.
• Position ahead of the next infrastructure upgrade cycle by scanning the 42 power grid technology and infrastructure stocks while these grid and hardware plays are still being priced quietly.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com